Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Aktueller Standort:
> This Story

Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment



Rad Oncology Homepage

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

Q & A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Access to proton therapy increasing for pediatric patients Young cancer patients have the most to gain from proton treatment

Hypofractionated radiotherapy no worse than conventional RT, says study No difference in progression and survival

Public-private partnership replaces 50-year old radiotherapy equipment in Guatemala Upgrading to Varian Halcyon system

Proton therapy market continues decline after 2015 high point: report By comparison, investment in 2018 dropped 62 percent

ViewRay to supply UK's GenesisCare with country's first MRIdian systems

by John R. Fischer , Staff Reporter
ViewRay Inc. is set to deliver the first of Great Britain’s MRIdian MR-guided radiotherapy systems as part of a new partnership between it and the cancer service provider, GenesisCare.

Deployed within the GenesisCare network, the first two systems will offer oncologists the ability to leverage soft-tissue imaging for the visualization of tumors, personalizing treatment with greater accuracy in the delivery of high-quality, image-guided, adaptive radiotherapy.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"Combining an MR scanner with a linear accelerator is the way of the future in radiotherapy, allowing us to see – for the first time – what's really happening inside the body during treatment,” Aldo Rolfo, executive manager for GenesisCare Europe, said in a statement. “This will enable our clinicians to offer truly personalized radiotherapy by adapting treatment in real time, to better target tumors and minimize side effects for patients."

The system integrates MR technology, radiation delivery, and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered, with its application of MR guidance reducing uncertainty involved in treatment.

Installation of the solution follows an earlier installation and commissioning this year at the University Clinic Heidelberg in Germany, as well as the awarding of a tender for installation at Centre Georges-François Leclerc in France.

In addition, the system is now equipped with MR pulse sequencing, higher image resolution, improvement in MR noise-to-signal ratio; and the integration of diffusion-weighted imaging, features showcased earlier this year at ESTRO 2018 in Barcelona, Spain.

Comprising more than 2,500 healthcare professionals and supporting staff members, GenesisCare delivers radiotherapy to more than 160,000 patients annually at 12 centers throughout the U.K., 21 in Spain and 30 in Australia.

"The reach of the GenesisCare network is vast and their investment in MRIdian is a testament to its industry-leading innovation for on-table adaptive therapy,” Scott Drake, president and CEO of ViewRay, said in a statement. “We are proud to be revolutionizing the field of radiation oncology."

News of MRIdian’s arrival has already been met with warm welcomes and cheers from Britain’s radiology community. #ViewRay MRIdian will be the focus of a new network of experienced #SABR clinicians and treatment teams, dedicated to bringing top flight IGRT and clinical trials to more patients,” tweeted cancer consultant specialist and oncologist Dr. James Good of Queen Elizabeth Hospital in Birmingham. “Delighted to be part of this effort…”

The system was cleared by the FDA in 2012 and CE marked in 2014.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Alle Gesundheitsdienstleister-Tools anzeigen
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifiziert
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Service-Techniker Forum
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.